TRex Bio prices $117M IPO to support immune drug work

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 09 Oct, 10:59 UTC

Eli Lilly is the largest equity holder in TRex, which is developing drugs that treat immunological conditions by activating “Treg” cells.